Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label lead-in tolerability period and an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spasticity of the lower limb

Trial Profile

Prospective, double-blind, placebo-controlled, randomized, multi-center study with an open-label lead-in tolerability period and an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of post-stroke spasticity of the lower limb

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Muscle spasticity
  • Focus Registrational; Therapeutic Use
  • Acronyms J-PLUS
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 07 Jun 2023 According to a Merz Therapeutics media release, the company received from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) for the use of XEOMIN for the treatment of focal spasticity of the lower limb affecting the ankle joint.
    • 23 Jun 2021 According to a Merz Therapeutics, Teijin Pharma Limited media release, based on the phase-III clinical trials conducted by Merz in Japan, Teijin Pharma has been granted additional approval with partial changes in the obtained approval by Japan's Ministry of Health, Labor and Welfare (MHLW) to market Xeomin (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of lower limb spasticity.
    • 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top